Skip to content

Electro-Entero-Graphy (EEnG) for non-invasive diagnosis of motility disorders of the bowel

Electro-Entero-Graphy (EEnG) for non-invasive diagnosis of motility disorders of the bowel - non-CoMoti

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51036
Enrollment
80
Registered
2021-01-19
Start date
2021-02-25
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

constipation obstruction

Interventions

All participants are asked to fast at least 4 hours (3 hours for babies

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
No minimum to 99 Years

Inclusion criteria

Inclusion criteria: All subjects: babies/children 18 years. For patients

Exclusion criteria

Exclusion criteria: All subjects: - For adults: BMI > 27 kg/m2 - For babies/children: weight for length > 2.5 standard deviation of WHO Child Growth Standard - Pregnancy - Diabetes - Any food intolerance - Intestinal stoma - Continuous tube feeding Healthy controls: - Any known gastro-intestinal disorders - Use of laxatives in the past two years Patients: - (partially) resected small intestines and/or colon - inflammatory bowel diseases

Design outcomes

Primary

MeasureTime frame
The primary study parameter is the relative power increase (pre-prandial vs. post-prandial) of the EEnG signal (in mV/Hz^2) in the relevance frequency region for colonic motility. This power increase can then be compared between healthy subjects and patients to investigate whether colonic motility can be measured using EEnG and also whether EEnG could be used as diagnostic tool for colonic motility disorders.

Secondary

MeasureTime frame
The questionnaires are summarized in a grand total score, which can be used to compare the burden of the EEnG procedure with the Gold Standard procedures.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)